Predictive Oncology (NASDAQ: POAI), a knowledge-driven
company focused on applying artificial intelligence (“AI”) to personalized
medicine and drug discovery, today released financial results for its full year
ended December 31, 2019, as well as select corporate highlights. Among the
highlights, the company reported its securing of a $15.0 million equity line
with Oasis Capital, LLC, as well as its new subsidiary, Helomics, reaching
milestone sequencing tumor cases in partnership with UPMC Magee. “2019 was not
without its challenges for the entire healthcare technology industry, yet we
continued to execute on our business model, making a synergistic acquisition
and shoring up our balance sheet via a new $15.0 million equity line from Oasis
Capital,” Predictive Oncology CFO Bob Myers said in the news release. “Our
STREAMWAY line has maintained strong disposable product sales and we continue
to sell the STREAMWAY System.”
To view the full press release, visit http://ibn.fm/EA4KG
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three
segments (Domestic, International and other), which contain four subsidiaries;
Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies
artificial intelligence to its rich data gathered from patient tumors to both
personalize cancer therapies for patients and drive the development of new
targeted therapies in collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists oncologists in
individualizing patient treatment decisions, by providing an evidence-based
roadmap for therapy. In addition to its proprietary precision oncology
platform, Helomics offers boutique CRO services that leverage its TruTumor(TM),
patient-derived tumor models coupled to a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its clients’ specific
needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid
approach to growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform kits will assist researchers and clinicians
to identify which cancer cells bind to specific biomarkers. Once the biomarkers
are identified they can be used in TumorGenesis’ Oncology Capture Technology
Platforms which isolate and help categorize an individual patient’s
heterogeneous tumor samples to enable the development of patient specific
treatment options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented and FDA
cleared STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and others, within a
medical facility, through both domestic and international divisions. The
company has achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
